Sign in Subscribe
Antiarthritic agents

Advances in Rheumatoid Arthritis Research: CTLA4 and UCP2 as Potential Therapeutic Targets

Strategic Insights

— 2 min read

Scientists at Sun Yat-Sen University have made significant strides in understanding the mechanisms behind rheumatoid arthritis, a chronic autoimmune disease that causes inflammation and pain in the joints. By investigating the role of regulatory T cells (Tregs) in the disease, researchers have identified two key players: CTLA4 and UCP2. These molecules are crucial in maintaining immune balance, but their dysfunction can lead to autoimmune responses. In their study, the team discovered that UCP2 disrupts metabolic homeostasis, downregulating Carnitine Palmitoyltransferase 2 (CPT2) and impairing fatty acid oxidation (FAO). This metabolic shift results in reduced Treg suppressive capacity and increased pro-inflammatory effects in rheumatoid arthritis. The researchers propose UCP2 as a potential therapeutic target for preventing autoimmune responses and mitigating the disease.

Key Takeaways:

  • CTLA4 is crucial for sustaining Treg function, while UCP2 plays a key role in linking glycolysis and fatty acid oxidation pathways.
  • Tregs in rheumatoid arthritis were predominantly characterized by a CD25intCTLA4intFOXP3intCD4high phenotype.
  • Elevated expression of UCP2 in RA Tregs disrupted metabolic homeostasis by downregulating CPT2, impairing FAO, and reducing CTLA4 cell surface accumulation.
  • Impaired FAO triggered caveolae-mediated endocytosis, leading to reduced Treg suppressive capacity.
  • UCP2 inhibition attenuated the pro-inflammatory effects of RA T cells in a human-SCID chimeric mouse model.
  • The research established a critical link between CTLA4 endocytosis and UCP2-mediated metabolic shift in Tregs, identifying UCP2 as a potential therapeutic target for preventing RA autoimmunity.
  • This study was funded by the National Natural Science Foundation of China and the Guangdong Natural Science Foundation.
  • The research was published in Molecular Medicine (31(1):1-17) on an unspecified date.

Statistics:

  • 10-20% of Tregs in rheumatoid arthritis exhibited a CD25intCTLA4intFOXP3intCD4high phenotype. (Source: Molecular Medicine)
  • 75% of CPT2 downregulation was observed in rheumatoid arthritis Tregs compared to healthy individuals. (Source: Molecular Medicine)
  • The study used a human-SCID chimeric mouse model to investigate the effects of UCP2 inhibition on RA T cells.
  • A free version of the journal article is available at https://doi.org/10.1186/s10020-025-01372-6.

Sources:

  • NewsRx. New Findings Reported from Sun Yat-Sen University Describe Advances in Rheumatoid Arthritis (Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4intFOXP3int regulatory T-cell production in rheumatoid arthritis). Health & Medicine Week. October 31, 2025; p 2951.
  • Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4intFOXP3int regulatory T-cell production in rheumatoid arthritis. Molecular Medicine, 2025,31(1):1-17. (Molecular Medicine - https://molmed.biomedcentral.com)
  • Jiawen Han, Zhongyang Zhou, Hongxia Wang, Yuxin Chen, Wuguo Li, Meiqin Dai, Jing Bian, Erming Zhao, Jiaying He, Xinyao Zhang, Huanfa Yi, and Lan Shao.

Read more